Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum.
Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum.
复制标题
激素治疗用于治疗复发性低级别浆液性卵巢癌或腹膜癌。
DOI：
10.1016/j.ygyno.2012.02.037
复制
发表时间：
2012-06
影响因子：
4.7
通讯作者：
Deavers M
中科院分区：
文献类型：
--
作者：
Gershenson DM;Sun CC;Iyer RB;Malpica AL;Kavanagh JJ;Bodurka DC;Schmeler K;Deavers M
确定激素疗法对复发性低级别卵巢浆液性癌或腹膜癌患者是否有效。我们检索了部门数据库，查找 1989 年至 2009 年间在我们机构接受激素治疗的经组织学确诊、可评估、复发性低级别浆液性卵巢癌或腹膜癌患者。我们回顾性审查了患者的医疗记录，包括人口统计、疾病、激素治疗以及雌激素受体和孕激素受体表达数据。我们使用实体瘤 1.1 版中的反应评估标准来确定患者对激素治疗的反应。由于患者可能接受了不止一种可评估的激素治疗方案，因此我们选择将结果指标定义为“患者方案”。还计算了中位疾病进展时间（TTP）和总生存期（OS）。还进行了回归分析。我们确定了 64 名患有复发性低度恶性卵巢或腹膜浆液性癌的患者。患者的中位 TTP 和中位 OS 分别为 7.4 个月和 78.2 个月。患者接受了 89 种独立的激素治疗方案，总体缓解率为 9%（6 例完全缓解，2 例部分缓解）。 61% 的患者方案实现了至少 6 个月的 6 个月无进展生存期。涉及 ER+/PR+ 疾病的患者方案产生的中位 TTP（8.9 个月）比涉及 ER+/PR- 疾病的患者方案（6.2 个月；p = 0.053）更长。这种差异接近但未达到统计显着性。激素疗法对复发性低级别卵巢或腹膜浆液性癌患者具有中等抗肿瘤活性。需要进一步研究以确定 ER/PR 表达状态是否是这种罕见癌症亚型的预测生物标志物。
To determine whether hormonal therapies have efficacy in patients with recurrent low-grade serous carcinoma of the ovary or peritoneum. We searched departmental databases for patients with histologically-confirmed, evaluable, recurrent low-grade serous ovarian or peritoneal carcinoma who received hormonal therapy at our institution between 1989 and 2009. We retrospectively reviewed patients' medical records for demographic, disease, hormonal therapy, and estrogen receptor and progesterone receptor expression data. We used the Response Evaluation Criteria in Solid Tumors version 1.1 to determine patients' responses to hormonal therapy. Because patients could have received more than one evaluable hormonal therapy regimen, we chose to define the outcome metric as “patient-regimens.” Median time to disease progression (TTP) and overall survival (OS) were also calculated. Regression analysis was also performed. We identified 64 patients with recurrent low-grade serous carcinoma of the ovary or peritoneum. Patients' median TTP and median OS were 7.4 and 78.2 months, respectively. Patients received 89 separate hormonal patient-regimens, which produced an overall response rate of 9% (6 complete responses and 2 partial responses). Sixty-one percent of the patient-regimens resulted in a 6-month progression-free survival duration of at least 6 months. Patient-regimens involving ER+/PR+ disease produced a longer median TTP (8.9 months) than patient-regimens involving ER+/PR- disease did (6.2 months; p = 0.053). This difference approached but did not reach statistical significance. Hormonal therapies have moderate anti-tumor activity in patients with recurrent low-grade serous carcinoma of the ovary or peritoneum. Further study to determine whether ER/PR expression status is a predictive biomarker for this rare cancer subtype is warranted.
登录
查看更多内容
影响因子：
8.4
作者：
Eisenhauer, E. A.;Therasse, P.;Verweij, J.
通讯作者：
Verweij, J.
影响因子：
4.7
作者：
del Carmen, MG;Fuller, AF;Seiden, MV
通讯作者：
Seiden, MV
影响因子：
50.5
作者：
Liedtke, C.;Broglio, K.;Gonzalez-Angulo, A. M.
通讯作者：
Gonzalez-Angulo, A. M.
影响因子：
7.2
作者：
Gershenson, David M.;Sun, Charlotte C.;Bodurka, Diane C.
通讯作者：
Bodurka, Diane C.
影响因子：
5.6
作者：
Malpica, Anais;Deavers, Michael T.;Silva, Elvio G.
通讯作者：
Silva, Elvio G.